These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8118271)
41. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients]. Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189 [TBL] [Abstract][Full Text] [Related]
42. Effect of cellular DNA content on the prognosis of epithelial ovarian cancers. Ozalp S; Yalcin OT; Gulbas Z; Tanir HM; Minsin T Gynecol Obstet Invest; 2001; 52(2):93-7. PubMed ID: 11586035 [TBL] [Abstract][Full Text] [Related]
43. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics. Flezar MS; But I; Kavalar R; Us-Krasovec M Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085 [TBL] [Abstract][Full Text] [Related]
44. [Granulosa cell tumor of the ovary: retrospective study of 17 cases]. Rebstock LE; Leufflen L; Leroux A; Harter V; Verhaeghe JL; Marchal F Gynecol Obstet Fertil; 2014 May; 42(5):331-3. PubMed ID: 24394321 [TBL] [Abstract][Full Text] [Related]
45. [Significance of flow cytometry in the prognosis of tumors of the kidney in adults]. Sibert L; Laquerrière A; Czernichow P; Dadoun D; Hemet J; Grise P Ann Urol (Paris); 1989; 23(6):476-81. PubMed ID: 2694924 [TBL] [Abstract][Full Text] [Related]
46. [Renal cell carcinoma: DNA cytometry and its clinical significance. An 8 year survival study]. al-Abadi H; Nagel R Helv Chir Acta; 1991 Sep; 58(3):331-4. PubMed ID: 1769855 [TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of DNA quantification by flow cytometry in ovarian tumors. Kim YT; Zhao M; Kim SH; Lee CS; Kim JH; Kim JW Int J Gynaecol Obstet; 2005 Mar; 88(3):286-91. PubMed ID: 15733883 [TBL] [Abstract][Full Text] [Related]
48. [Flow cytometry detected S-phase fraction and ploidy as prognostic parameters in primary, node-negative breast cancer]. Winter K; Eidtmann H; Jonat W Geburtshilfe Frauenheilkd; 1994 May; 54(5):291-4. PubMed ID: 8050690 [TBL] [Abstract][Full Text] [Related]
49. Granulosa cell tumors of the ovary: prognostic factors and outcome. Malmström H; Högberg T; Risberg B; Simonsen E Gynecol Oncol; 1994 Jan; 52(1):50-5. PubMed ID: 8307501 [TBL] [Abstract][Full Text] [Related]
50. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654 [TBL] [Abstract][Full Text] [Related]
51. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study. Verbruggen MB; van Diest PJ; Baak JP; Broeckaert MA; Kenemans P; Verheijen RH Int J Gynecol Pathol; 2009 Jan; 28(1):35-40. PubMed ID: 19047910 [TBL] [Abstract][Full Text] [Related]
52. Flow cytometrical DNA- and clinical parameters in the prediction of prognosis in stage I-II endometrial carcinoma. Lindahl B; Gullberg B Anticancer Res; 1991; 11(1):397-401. PubMed ID: 2018376 [TBL] [Abstract][Full Text] [Related]
53. DNA content as prognostic factor in cervix carcinoma stage IB-III treated with radiotherapy. Lutgens LC; Schutte B; de Jong JM; Thunnissen FB Gynecol Oncol; 1994 Sep; 54(3):275-81. PubMed ID: 8088604 [TBL] [Abstract][Full Text] [Related]
54. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114 [TBL] [Abstract][Full Text] [Related]
56. Multivariate analysis of DNA ploidy, steroid hormone receptors, and CA 125 as prognostic factors in ovarian carcinoma: a prospective study. Eissa S; Khalifa A; Laban M; Mohamed MK; Elian A Nutrition; 1995; 11(5 Suppl):622-6. PubMed ID: 8748237 [TBL] [Abstract][Full Text] [Related]
57. Prognostic assessment in stage I ovarian cancer using a discriminant analysis with clinicopathological and DNA flow cytometric data. Punnonen R; Kallioniemi OP; Mattila J; Koivula T Gynecol Obstet Invest; 1989; 27(4):213-6. PubMed ID: 2744626 [TBL] [Abstract][Full Text] [Related]
58. DNA flow cytometry in early breast cancer: a step in the right direction. Osborne CK J Natl Cancer Inst; 1989 Sep; 81(18):1344-5. PubMed ID: 2778818 [No Abstract] [Full Text] [Related]
59. DNA cytometry of pure dysgerminomas of the ovary. Oud PS; Soeters RP; Pahlplatz MM; Hermkens HG; Beck HL; Reubsaet-Veldhuizen J; Vooijs GP Int J Gynecol Pathol; 1988; 7(3):258-67. PubMed ID: 3182171 [TBL] [Abstract][Full Text] [Related]
60. Carcinoma of the ovary. Heintz AP; Odicino F; Maisonneuve P; Beller U; Benedet JL; Creasman WT; Ngan HY; Pecorelli S Int J Gynaecol Obstet; 2003 Oct; 83 Suppl 1():135-66. PubMed ID: 14763172 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]